{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T05:39:21Z","timestamp":1778132361844,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Vedolizumab, an anti-integrin antibody, is effective for moderate to severe ulcerative colitis and Crohn\u2019s disease treatment with a good safety profile due to its gut selective mechanism of action. Upper respiratory tract vedolizumab adverse events are common; however, they are mild and do not require treatment withdrawal. Herein, we present a 39-year-old patient under vedolizumab treatment for ulcerative colitis who presented acute severe interstitial lung injury that necessitated vedolizumab withdrawal and systemic steroids administration.<\/jats:p>","DOI":"10.1097\/meg.0000000000002197","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T18:41:52Z","timestamp":1622745712000},"page":"e1057-e1059","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis"],"prefix":"10.1097","volume":"33","author":[{"given":"Evripidis D.","family":"Rizos","sequence":"first","affiliation":[{"name":"Hepatogastroenterology Unit, 2nd Department of Internal Medicine - Propaedeutic, Research Institute and Diabetes Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira-Markela","family":"Antonogiannaki","sequence":"additional","affiliation":[{"name":"2nd Pulmonary Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Chatzidakis","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Unit, 2nd Department of Internal Medicine - Propaedeutic, Research Institute and Diabetes Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Kallieri","sequence":"additional","affiliation":[{"name":"2nd Pulmonary Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoi","family":"Tsilogianni","sequence":"additional","affiliation":[{"name":"2nd Pulmonary Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effrosyni D.","family":"Manali","sequence":"additional","affiliation":[{"name":"2nd Pulmonary Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Economopoulos","sequence":"additional","affiliation":[{"name":"2nd Department of Radiology, General University Hospital \u201cAttikon\u201d, Medical School, National and Kapodistrian University, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Triantafyllou","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Unit, 2nd Department of Internal Medicine - Propaedeutic, Research Institute and Diabetes Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros A.","family":"Papiris","sequence":"additional","affiliation":[{"name":"2nd Pulmonary Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Polymeros","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Unit, 2nd Department of Internal Medicine - Propaedeutic, Research Institute and Diabetes Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjmed.2019.07.007","article-title":"Pulmonary manifestations of inflammatory bowel disease.","volume":"133","author":"Massart","year":"2020","journal-title":"Am J Med"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.5114\/aoms.2015.56343","article-title":"Pulmonary manifestations of inflammatory bowel disease.","volume":"11","author":"Majewski","year":"2015","journal-title":"Arch Med Sci"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ecco-jcc\/jjv135","article-title":"Six cases of lung injury following anti-tumour necrosis factor therapy for inflammatory bowel disease.","volume":"9","author":"Lee","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R5-20240821","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"170082","DOI":"10.1183\/16000617.0082-2017","article-title":"Long-term macrolides in diffuse interstitial lung diseases.","volume":"26","author":"Faverio","year":"2017","journal-title":"Eur Respir Rev"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4291\/wjgp.v5.i4.560","article-title":"Patterns of airway involvement in inflammatory bowel diseases.","volume":"5","author":"Papanikolaou","year":"2014","journal-title":"World J Gastrointest Pathophysiol"},{"key":"R8-20240821","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R9-20240821","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease.","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"R10-20240821","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3748\/wjg.v24.i23.2457","article-title":"Vedolizumab for inflammatory bowel disease: from randomized controlled trials to real-life evidence.","volume":"24","author":"Scribano","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2019.09.016","article-title":"New-onset diffuse parenchymal lung disease in a 52-year-old woman with ulcerative colitis.","volume":"158","author":"De Backer","year":"2020","journal-title":"Gastroenterology"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ajg.2017.395","article-title":"Pulmonary manifestation of Crohn\u2019s disease developed under treatment with vedolizumab.","volume":"113","author":"Lissner","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R13-20240821","doi-asserted-by":"crossref","first-page":"e592","DOI":"10.1097\/MJT.0000000000000627","article-title":"Vedolizumab-associated acute respiratory distress syndrome.","volume":"25","author":"Nambiar","year":"2018","journal-title":"Am J Ther"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1164\/rccm.201806-1056IM","article-title":"Necrobiotic pulmonary nodules of Crohn\u2019s disease in a patient receiving vedolizumab.","volume":"199","author":"Myc","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20240821","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab.","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fimmu.2017.00764","article-title":"Clinical response to vedolizumab in ulcerative colitis patients is associated with changes in integrin expression profiles.","volume":"8","author":"Fuchs","year":"2017","journal-title":"Front Immunol"},{"key":"R17-20240821","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MIB.0000000000001029","article-title":"The \u03b14\u03b21 homing pathway is essential for ileal homing of Crohn\u2019s disease effector T cells in vivo.","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"S-865","DOI":"10.1016\/S0016-5085(15)32933-4","article-title":"Skin and joint side effects in a subpopulation of anti-TNF experienced IBD patients, who respond to a treatment with vedolizumab, a humanized A4b7 integrin antibody.","volume":"148","author":"Drvarov","year":"2015","journal-title":"Gastroenterology"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:06:45Z","timestamp":1724364405000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":17,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002197","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}